ASH2019注目テーマ Late-Breaking Abstracts Session #1

小児・AYA世代の初回の再発B-ALLに対し
ブリナツモマブは化学療法より再寛解導入に有用 A Randomized Phase 3 Trial of Blinatumomab vs. Chemotherapy as Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children’s Oncology Group Study AALL1331

Patrick A. Brown（Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD）